ArticleBritish journal of haematology2019
Acute myeloid leukaemia niche regulates response to L-asparaginase.
Article in British journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- From ALL to Myeloid and NK Malignancies: Operationalizing "ASNS-Low" for L-Asparaginase Repurposing and Combination Therapy.Biomolecules · 2026Review
- Understanding and Targeting Metabolic Vulnerabilities in Acute Myeloid Leukemia: An Updated Comprehensive Review.Cancers · 2025Review
- Review
- Multifaceted role of GCN2 in tumor adaptation and therapeutic targeting.Translational oncology · 2024Review
- Glutamine and leukemia research: progress and clinical prospects.Discover oncology · 2024Review
- The recombinant L-lysine α-oxidase from the fungus Trichoderma harzianum promotes apoptosis and necrosis of leukemia CD34 + hematopoietic cells.Microbial cell factories · 2024Article
- Targeting Glutamine Metabolism as an Attractive Therapeutic Strategy for Acute Myeloid Leukemia.Current treatment options in oncology · 2023Review
- Review
- Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy.Cancers · 2022Review
- Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group.Pediatric blood & cancer · 2022Article
- Exploring the Metabolic Landscape of AML: From Haematopoietic Stem Cells to Myeloblasts and Leukaemic Stem Cells.Frontiers in oncology · 2022Review
- Oncogenic Mechanisms and Therapeutic Targeting of Metabolism in Leukemia and Lymphoma.Cold Spring Harbor perspectives in medicine · 2021Review
- Review
- Prognostic significance of esterase gene expression in multiple myeloma.British journal of cancer · 2021Article
- Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies.Frontiers in oncology · 2021Review
- Insights on the Interplay between Cells Metabolism and Signaling: A Therapeutic Perspective in Pediatric Acute Leukemias.International journal of molecular sciences · 2020Review
- Acute myeloid leukaemia niche regulates response to L-asparaginase.British journal of haematology · 2019Article
- Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia.BMC biology · 2019Review
- Moving Myeloid Leukemia Drug Discovery Into the Third Dimension.Frontiers in pediatrics · 2019Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eradicating the malignant stem cell is the ultimate challenge in the treatment of leukaemia. Leukaemic stem cells (LSC) hijack the normal haemopoietic niche, where they are mainly protected from cytotoxic drugs. The anti-leukaemic effect of L-asparaginase (ASNase) has been extensively investigated in acute lymphoblastic leukaemia, but only partially in acute myeloid leukaemia (AML). We explored the susceptibility of AML-LSC to ASNase as well as the role of the two major cell types that constitute the bone marrow (BM) microenvironment, i.e., mesenchymal stromal cells (MSC) and monocytes/macrophages. Whilst ASNase was effective on both CD34
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.